Literature DB >> 22131003

Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.

Harris S Soifer1, Troels Koch, Johnathan Lai, Bo Hansen, Anja Hoeg, Henrik Oerum, C A Stein.   

Abstract

Antisense oligodeoxyribonucleotides have been used for decades to achieve sequence-specific silencing of gene expression. However, all early generation oligonucleotides (e.g., those with no other modifications than the phosphorothioate backbone) are inactive in vitro unless administered using a delivery vehicle. These delivery vehicles are usually lipidic but can also be polyamines or some other particulate reagent. We have found that by employing locked nucleic acid (LNA) phosphorothioate gap-mer nucleic acids of 16 mer or less in length, and by carefully controlling the plating conditions of the target cells and duration of the experiment, sequence-specific gene silencing can be achieved at low micromolar concentrations in vitro in the absence of any delivery vehicle. This process of naked oligonucleotide delivery to achieve gene silencing in vivo, which we have termed gymnosis, has been observed in many both adherent and nonadherent cell lines against several different targets genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22131003     DOI: 10.1007/978-1-61779-424-7_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  33 in total

1.  PEI-complexed LNA antiseeds as miRNA inhibitors.

Authors:  Maren Thomas; Kerstin Lange-Grünweller; Eyas Dayyoub; Udo Bakowsky; Ulrike Weirauch; Achim Aigner; Roland K Hartmann; Arnold Grünweller
Journal:  RNA Biol       Date:  2012-08-01       Impact factor: 4.652

Review 2.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

3.  Hiding in the Shadows: CPOX Expression and 5-ALA Induced Fluorescence in Human Glioma Cells.

Authors:  Nikolay Pustogarov; Dmitriy Panteleev; Sergey A Goryaynov; Anastasia V Ryabova; Ekaterina Y Rybalkina; Alexander Revishchin; Alexander A Potapov; Galina Pavlova
Journal:  Mol Neurobiol       Date:  2016-09-19       Impact factor: 5.590

4.  MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.

Authors:  Yongxia Wu; Jessica Heinrichs; David Bastian; Jianing Fu; Hung Nguyen; Steven Schutt; Yuejun Liu; Junfei Jin; Chen Liu; Qi-Jing Li; Changqing Xia; Xue-Zhong Yu
Journal:  Blood       Date:  2015-07-02       Impact factor: 22.113

Review 5.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.

Authors:  Daniela Castanotto; Min Lin; Claudia Kowolik; Troels Koch; Bo Rode Hansen; Henrik Oerum; Cy A Stein
Journal:  Mol Ther       Date:  2016-03-10       Impact factor: 11.454

7.  6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells.

Authors:  Xiaowei Zhang; Daniela Castanotto; Sangkil Nam; David Horne; Cy Stein
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

8.  Quantum mechanical studies of DNA and LNA.

Authors:  Troels Koch; Irene Shim; Morten Lindow; Henrik Ørum; Henrik G Bohr
Journal:  Nucleic Acid Ther       Date:  2014-02-03       Impact factor: 5.486

9.  Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells.

Authors:  Hosiana Abewe; Savitha Deshmukh; Amey Mukim; Nadejda Beliakova-Bethell
Journal:  J Immunol Methods       Date:  2019-10-17       Impact factor: 2.303

10.  Methods to Investigate miRNA Function: Focus on Platelet Reactivity.

Authors:  Alix Garcia; Sylvie Dunoyer-Geindre; Richard J Fish; Marguerite Neerman-Arbez; Jean-Luc Reny; Pierre Fontana
Journal:  Thromb Haemost       Date:  2020-10-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.